Evidence map›Paper›PMID 29845329›Full record

Trial reportThe AAPS journal2018

A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy.

Dongwoo Chae, Chung Mo Nam, Joo Hoon Kim, Choong-Kun Lee, Seung-Seob Kim, Hyo Song Kim, Minkyu Jung, Jae Ho Cheong, Hyun Cheol Chung, Sun Young Rha and 1 more

Open access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The AAPS journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Dongwoo ChaeDepartment of Pharmacology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Chung Mo NamDepartment of Preventive Medicine and Public Health, Yonsei University College of Medicine, Seoul, South Korea.
Joo Hoon KimDepartment of Oncology, Good Morning Hospital, Pyeongtaek-si, Gyeonggi-do, South Korea.
Choong-Kun LeeDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Seung-Seob KimDepartment of Radiology, Yonsei University College of Medicine, Seoul, South Korea.
Hyo Song KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Minkyu JungDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Jae Ho CheongSong-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
Hyun Cheol ChungDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Sun Young RhaDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea. rha7655@yuhs.ac.
Kyungsoo ParkDepartment of Pharmacology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea. kspark@yuhs.ac.
Yonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effects of different patient factors and dose levels of chemotherapeutic agents on clinical outcomes in advanced gastric cancer are not as yet fully characterized. We aimed at developing an integrative model that incorporates dose and covariate information to predict tumor growth and patient survival in advanced gastric cancer patients treated with trastuzumab (T), 5-FU(F)/capecitabine (X) (F or X), and cisplatin (P). Sixty-nine patients (training dataset) were used for model building and a separate 86 patients (test dataset) for model validation. A fraction of tumor cells sensitive to each drug was incorporated as a model parameter, and T was assumed as cytostatic and X/F and P as cytotoxic. Cox proportional hazards analyses were performed on model parameters and patient covariates. The model well described the time course of observed tumor size changes, and revealed that the pretreatment tumor growth rate constant k

Indexed as

Models, BiologicalAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDatasets as TopicDisease ProgressionDose-Response Relationship, DrugErb-b2 Receptor Tyrosine KinasesFemaleHumansMaleMiddle AgedNeoplasm GradingPrognosisProgression-Free SurvivalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabdose-response modelHER2-positive gastric cancerprediction modeltrastuzumabtumor progression model

Identifiers

PMID29845329
OpenAlexW2806670123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.